DNA damage response (DDR) gene mutations (mut), mut load, and sensitivity to chemotherapy plus immune checkpoint blockade in urothelial cancer (UC).

Authors

null

Matt D. Galsky

Icahn School of Medicine at Mount Sinai, New York, NY

Matt D. Galsky , Andrew V. Uzilov , Russell Bailey McBride , Huan Wang , Vaibhav G. Patel , John Sfakianos , Li Wang , Nicholas Akers , Gopa Iyer , David B. Solit , Takuro Saito , Mireia Castillo-Martin , Noah M. Hahn , Sumanta K. Pal , Mark T. Fleming , Ralph J. Hauke , Bojan Losic , Sacha Gnjatic , Rong Chen , Nina Bhardwaj

Organizations

Icahn School of Medicine at Mount Sinai, New York, NY, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, Genetics and Genomic Sciences, The Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY, Memorial Sloan Kettering Cancer Center, New York, NY, Johns Hopkins University, Baltimore, MD, City of Hope, Duarte, CA, US Oncology Research, Virginia Oncology Associates, Hampton, VA, Nebraska Cancer Specialists, Omaha, NE, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY

Research Funding

Other Foundation

Background: Somatic mut in DDR genes have been associated with increased sensitivity to cisplatin in UC. Higher mut load has correlated with response to immune checkpoint blockade. We hypothesized that DDR mut result in higher mut load and DDR mut UC may be particularly sensitive to both chemotherapy and immune checkpoint blockade. Methods: Three cohorts were utilized: (1) TCGA UC cohort (n = 389), (2) Mount Sinai (MS) cohort (n = 67) of UC (cystectomy) specimens subjected to targeted exome sequencing for 341 genes (MSK-IMPACT), and (3) Phase 2 trial of gemcitabine, cisplatin, plus ipilimumab (GCI) in metastatic UC from which 28/36 enrolled patients (pts) had specimens suitable for whole exome sequencing. DDR mut were defined as somatic alterations in one of 52 genes. Deleterious (del) mut were defined as nonsense, frameshift, splice site, or hotspot point mut. Results: The mut load using all genes in the TCGA cohort, and restricted to the 341 IMPACT genes, were highly correlated (rs= 0.81, p < 0.001). Associations between del DDR mut and mut load are shown (Table). In the MS cohort, CD8+cells/mm2 by IHC were higher in tumors with del DDR mut versus no DDR mut (p = 0.04). In the GCI cohort, the sensitivity, specificity, positive predictive value, and negative predictive value of a del DDR mut for objective response to treatment was 40.9% (95% CI 20.7-63.7%), 86.7% (95% CI 42.1-99.4%), 90% (55.5-99.8%), and 31.6% (95% CI 12.6-56.6%), respectively. Median progression-free survival in the GCI cohort was 308 days (95% CI 270-NR) in del DDR mut and 196 days (95% CI 185-372) in others (p = 0.24). Notably, 2/9 pts with del DDR mutations, and with the highest mut loads, achieved complete responses after GCI and are alive without evidence of disease at 2.1+ and 1.8+ years. Conclusions: DDR mut are associated with higher mut load in UC, a high likelihood of response to GCI, and may identify a subset of pts achieving durable disease control. GC plus PD-1/PD-L1 blockade should be explored in DDR mut UC. Clinical trial information: NCT01524991

CohortNDel DDR mutMut Load SNV/tumor, median (range)
p
Del DDR mutOther
TCGA38928%271 (26-3617)148 (22-1016)< 0.001
MS6721%31 (17-66)18 (9-42)< 0.001
GCI2832%344 (101-4292)232 (84-1010)0.027

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2017 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Prostate Cancer and Urothelial Carcinoma

Track

Prostate Cancer,Urothelial Carcinoma,Prostate Cancer

Sub Track

Urothelial Carcinoma

Clinical Trial Registration Number

NCT01524991

Citation

J Clin Oncol 35, 2017 (suppl 6S; abstract 300)

DOI

10.1200/JCO.2017.35.6_suppl.300

Abstract #

300

Poster Bd #

E13

Abstract Disclosures